Cerevance Achieves Key Endpoints in Phase... - Cure Parkinson's
Cerevance Achieves Key Endpoints in Phase 1 Clinical Trial of Novel Parkinson’s Disease Drug CVN42
![Farooqji profile image](https://images.hu-production.be/avatars/d2bcede6695608a9d172b4c00f6b376c_small@2x_100x100.jpg)
Written by
![Farooqji profile image](https://images.hu-production.be/avatars/d2bcede6695608a9d172b4c00f6b376c_small@2x_100x100.jpg)
Farooqji
To view profiles and participate in discussions please or .
Read more about...
Not what you're looking for?
You may also like...
Cough syrup drug being trialed as Parkinson’s treatment
https://neurosciencenews.com/parkinsons-ambroxol-15712/
Ambroxol, a medication approved to treat...
Must Read: Gut Microbiota: A Novel Therapeutic Target for Parkinson’s Disease 24 June 2022
Novel Therapeutic Target for Parkinson’s Disease...
Parkinson's Drug Reduces Disease Markers in Breakthrough Trial
sounds promising what do you think?
https://www.sciencealert.com/parkinsons-drug-reduces-disease-m
Dr. Tom Foltynie of Cure Parkinson’s Addresses Bydureon (Exanatide) Phase III Trial.
in 2019 and contemplates starting the two year Phase III trial in October of 2019, but the video...
Annovis Announces Unblinding of the Buntanetap Phase III Data in Parkinson’s Disease
samples accounting for placebo....